Entrada Therapeutics Q3 EPS $(1.06) Misses $(0.95) Estimate, Sales $1.614M Miss $13.702M Estimate
Benzinga Newsdesk 11 months ago
EarningsEarnings MissesNews
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.95) by 11.58 percent. This is a 202.86 percent decrease over losses of $(0.35) per
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.95) by 11.58 percent. This is a 202.86 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $1.614 million which missed the analyst consensus estimate of $13.702 million by 88.22 percent. This is a 91.75 percent decrease over sales of $19.570 million the same period last year.